WST's 15.3% Rally Reflects HVP Strength, But Valuation Keeps Rating at WAIT

What happened

West Pharmaceutical's stock rallied 15.3% over the past three months, reaching $338, driven by strong high-value product growth, wider margins, and a raised 2026 outlook. The company's Q2 2026 results showed organic sales up 12.7%, gross margin expanding to 37.7%, and HVP components growing 20.4% year-to-date, fueled by biologics and GLP-1 demand. Management raised full-year guidance to $3.345-$3.380 billion in sales and $8.85-$9.05 adjusted EPS, reinforcing the market's premium growth narrative. However, the stock now trades at 42.9x P/E and 32.7x EV/EBITDA, which already prices in sustained HVP momentum and successful capacity conversions. This premium valuation leaves little room for disappointment, particularly with Q3 guidance of $820-$835 million and unquantified Dublin commercialization contributions.

Implication

Current valuation at $338 leaves no margin of safety, as the market already capitalizes strong HVP growth, margin expansion, and raised guidance. The next 90 days are critical: Q3 revenue must land within $820-$835 million and adjusted EPS within $2.14-$2.24, while gross margin should hold near 37.7%. Additionally, any explicit disclosure of Dublin drug-handling revenue or backlog would de-risk the story, but absence would raise doubts about back-half conversion. Until those checkpoints are cleared, the stock remains a WAIT, and investors should consider buying only on a pullback toward $300 or if Q3 exceeds guidance with margin stability. Conversely, trimming above $365 remains prudent if the stock gets ahead of fundamentals.

Thesis delta

The news confirms the operating strength already reflected in the master report: HVP growth, margin expansion, and raised guidance are indeed positive. However, it does not alter the core concern that valuation is stretched at 42.9x P/E, with limited upside unless Q3 proves exceptional. The investment thesis remains WAIT, with the same price targets: attractive entry near $300 and trim zone above $365.